$DFFN Management has really tested retail patience here but let’s see if we can build some momentum before the next covid-19 related PR(s). Here’s my approximate timeline for the coming weeks/months: Q2/3 2020: •European Phase 1A/1B clinical trial approval (late June). •Initiate European Phase 1A study of 24 patients (late June/early July). •US IND submission (late June/early July). Q3/4 2020: •US IND approval (late July). •Data from 24 patients in Phase 1A of European trial (Aug/Sept). •Initiate US Phase 2 trial (Aug/Sept). •Initiate European Phase 1B study of 200 patients, double-blinded study (Sept/Oct). Q4 2020 •Interim readout on 50 patients in European Phase 1B (Oct/Nov). Q1/2 2021: •Enrollment completion of 224 patients in European study (Jan-March 2021). •Final data readout of 224 patients in European Phase 1A/1B trial (April-June 2021). I didn’t include many US trial dates bc I don’t know much until the actual IND is filed in the coming weeks. GLTA.